APA
Click to copy
Moore, H., Barrett, C. D., Moore, E., Jhunjhunwala, R., McIntyre, R., Moore, P. K., … Yaffe, M. (2020). Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID‐19: Study design of the phase IIa STARS trial. Research and Practice in Thrombosis and Haemostasis.
Chicago/Turabian
Click to copy
Moore, H., Christopher D. Barrett, E. Moore, Rashi Jhunjhunwala, R. McIntyre, Peter K. Moore, Janice Wang, et al. “Study of Alteplase for Respiratory Failure in Severe Acute Respiratory Syndrome Coronavirus 2/COVID‐19: Study Design of the Phase IIa STARS Trial.” Research and Practice in Thrombosis and Haemostasis (2020).
MLA
Click to copy
Moore, H., et al. “Study of Alteplase for Respiratory Failure in Severe Acute Respiratory Syndrome Coronavirus 2/COVID‐19: Study Design of the Phase IIa STARS Trial.” Research and Practice in Thrombosis and Haemostasis, 2020.
BibTeX Click to copy
@article{h2020a,
title = {Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID‐19: Study design of the phase IIa STARS trial},
year = {2020},
journal = {Research and Practice in Thrombosis and Haemostasis},
author = {Moore, H. and Barrett, Christopher D. and Moore, E. and Jhunjhunwala, Rashi and McIntyre, R. and Moore, Peter K. and Wang, Janice and Hajizadeh, N. and Talmor, D. and Sauaia, A. and Yaffe, M.}
}
The coronavirus disease 2019 (COVID‐19) pandemic has caused a large surge of acute respiratory distress syndrome (ARDS). Prior phase I trials (non–COVID‐19) demonstrated improvement in pulmonary function in patients ARDS using fibrinolytic therapy. A follow‐up trial using the widely available tissue‐type plasminogen activator (t‐PA) alteplase is now needed to assess optimal dosing and safety in this critically ill patient population.